DK0502812T3 - Rekombinante antistoffer, som er specifikke for en vækstfaktorreceptor - Google Patents
Rekombinante antistoffer, som er specifikke for en vækstfaktorreceptorInfo
- Publication number
- DK0502812T3 DK0502812T3 DK92810056.9T DK92810056T DK0502812T3 DK 0502812 T3 DK0502812 T3 DK 0502812T3 DK 92810056 T DK92810056 T DK 92810056T DK 0502812 T3 DK0502812 T3 DK 0502812T3
- Authority
- DK
- Denmark
- Prior art keywords
- chain variable
- variable domain
- dna
- recombinant antibodies
- growth factor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP91810079 | 1991-02-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0502812T3 true DK0502812T3 (da) | 1996-09-02 |
Family
ID=8208816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK92810056.9T DK0502812T3 (da) | 1991-02-05 | 1992-01-27 | Rekombinante antistoffer, som er specifikke for en vækstfaktorreceptor |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0502812B1 (fr) |
JP (1) | JP3415171B2 (fr) |
AT (1) | ATE141329T1 (fr) |
AU (1) | AU662311B2 (fr) |
CA (1) | CA2060544C (fr) |
DE (1) | DE69212671T2 (fr) |
DK (1) | DK0502812T3 (fr) |
ES (1) | ES2091438T3 (fr) |
GR (1) | GR3020809T3 (fr) |
IE (1) | IE72959B1 (fr) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69334255D1 (de) * | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
CA2157767A1 (fr) * | 1993-03-09 | 1994-09-15 | Elaine M. Brate | Enzymes concues genetiquement et leurs conjugues pour essais diagnostiques |
IT1264083B1 (it) * | 1993-12-10 | 1996-09-10 | Enea Ente Nuove Tec | Procedimento per la produzione in piante di anticorpi ingegnerizzati, anticorpi prodotti e loro uso in diagnosi e terapia. |
NZ285395A (en) | 1994-05-02 | 1998-10-28 | Novartis Ag | Chimeric antibody, cancer treatment |
EP0739984A1 (fr) * | 1995-04-26 | 1996-10-30 | San Tumorforschungs-Gmbh | Polypeptides bivalents contenants aux moins deux domaines |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
EP1516628B1 (fr) * | 1995-07-27 | 2013-08-21 | Genentech, Inc. | Formulation de protéine stabile, lyophilisée et isotonique |
JP2014148555A (ja) * | 1995-07-27 | 2014-08-21 | Genentech Inc | タンパク質の処方 |
US5968511A (en) * | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
CN1214044C (zh) * | 1996-03-27 | 2005-08-10 | 基因技术股份有限公司 | ErbB3抗体 |
US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
DE19735105A1 (de) * | 1997-08-13 | 1999-03-04 | Univ Albert Ludwigs Freiburg | Transportsystem zur Einbringung von Proteinen in Zielzellen mit Hilfe eines Fusionsproteins, Nucleinsäurekonstrukte kodierend für die Komponenten des Transportsystems und Arzneimittel, die Komponenten des Transportsystems umfassen |
JP2003520195A (ja) | 1999-05-14 | 2003-07-02 | イムクローン システムズ インコーポレイティド | 上皮成長因子受容体アンタゴニストによる難治性ヒト腫瘍の処理 |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
ATE441433T1 (de) | 2000-05-19 | 2009-09-15 | Genentech Inc | Gennachweisverfahren zur verbesserung der wahrscheinlichkeit einer wirkungsvollen antwort auf eine krebstherapie mit einem erbb- antagonisten |
AU2003249533A1 (en) | 2002-07-04 | 2004-01-23 | Oncomab Gmbh | Neoplasm specific antibodies and uses thereof |
DE10311248A1 (de) | 2003-03-14 | 2004-09-30 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper |
EP1531162A1 (fr) | 2003-11-14 | 2005-05-18 | Heinz Vollmers | Anticorps SAM-6, spécifique d'adénocarcinome, et ses utilisations |
DE10353175A1 (de) | 2003-11-14 | 2005-06-16 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper mit fettsenkender Wirkung |
EP1812064A4 (fr) | 2004-11-19 | 2009-07-08 | Cornell Res Foundation Inc | Utilisation des cellules du recepteur du facteur de croissance endothelial vasculaire dans le traitement et la surveillance du cancer et dans le criblage d'agents chimiotherapeutiques |
CN101141981A (zh) | 2005-01-21 | 2008-03-12 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
EP2399605A1 (fr) | 2005-02-23 | 2011-12-28 | Genentech, Inc. | Extension du laps de temps avant progression de la maladie ou de la survie chez les patients atteints de cancer |
GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
WO2008109440A2 (fr) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Elément de prévision de la réponse à un inhibiteur de her |
CA3006428A1 (fr) | 2007-06-08 | 2008-12-18 | Genentech, Inc. | Marqueurs d'expression de gene de resistance tumorale a un traiteme r inhibiteur her2 |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
US8734795B2 (en) | 2008-10-31 | 2014-05-27 | Biogen Idec Ma Inc. | Light targeting molecules and uses thereof |
KR20130080871A (ko) | 2009-03-20 | 2013-07-15 | 제넨테크, 인크. | 이중특이적 항-her 항체 |
CN102421448A (zh) | 2009-05-29 | 2012-04-18 | 霍夫曼-拉罗奇有限公司 | Her2信号传导调控剂在表达her2的胃癌患者中 |
SI2536748T1 (sl) | 2010-02-18 | 2014-12-31 | Genentech, Inc. | Nevrogulinski antagonisti in njihova uporaba pri zdravljenju raka |
CN102844050B (zh) | 2010-02-19 | 2019-02-05 | 康奈尔大学 | 自身免疫性脱髓鞘疾病及其它自身免疫疾病或炎性疾病的治疗方法 |
WO2011146568A1 (fr) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Prédiction de réponses à un inhibiteur de her |
EP2643353A1 (fr) | 2010-11-24 | 2013-10-02 | Novartis AG | Molécules multi-spécifiques |
JP5766296B2 (ja) | 2010-12-23 | 2015-08-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用 |
BR112014003431A2 (pt) | 2011-08-17 | 2017-06-13 | Genentech Inc | anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor |
US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
AU2012346540C1 (en) | 2011-11-30 | 2019-07-04 | Genentech, Inc. | ErbB3 mutations in cancer |
EP2788500A1 (fr) | 2011-12-09 | 2014-10-15 | F.Hoffmann-La Roche Ag | Identification de non-répondeurs aux inhibiteurs de her2 |
BR112014024017A8 (pt) | 2012-03-27 | 2017-07-25 | Genentech Inc | Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3 |
CN104813168B (zh) | 2012-11-30 | 2017-10-20 | 霍夫曼-拉罗奇有限公司 | 需要pd‑l1抑制剂综合疗法的患者的鉴定 |
US20190151346A1 (en) | 2016-05-10 | 2019-05-23 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
WO2022161314A1 (fr) | 2021-01-27 | 2022-08-04 | 信达生物制药(苏州)有限公司 | Anticorps à un seul domaine contre cd16a et son utilisation |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
JP3105898B2 (ja) | 1988-04-16 | 2000-11-06 | セルテック リミテッド | 組換えdnaタンパクの製造方法 |
WO1989011533A1 (fr) | 1988-05-23 | 1989-11-30 | The United States Of America, As Represented By Th | Gene clone exprimant des anticorps reagissant avec le cancer ovarien chez la femme |
JP2761543B2 (ja) | 1988-08-17 | 1998-06-04 | 味の素株式会社 | ヒト癌原遺伝子産物に対するモノクローナル抗体及びそれを産生するハイブリドーマ |
EP0364096B1 (fr) * | 1988-09-06 | 2000-03-08 | Xoma Corporation | Eléments d'expression de gènes et production d'anticorps souris-humains chimériques |
DK0474727T3 (da) * | 1989-05-19 | 1998-01-12 | Genentech Inc | HER2 ekstracellulært domæne |
ES2204890T3 (es) * | 1991-03-06 | 2004-05-01 | Merck Patent Gmbh | Anticuerpos monoclonales humanizados. |
WO1993003741A1 (fr) * | 1991-08-22 | 1993-03-04 | Becton, Dickinson & Company | Procedes et compositions de traitements de cancers et de pronostic de reactions auxdits traitements |
-
1992
- 1992-01-23 AU AU10421/92A patent/AU662311B2/en not_active Ceased
- 1992-01-27 AT AT92810056T patent/ATE141329T1/de not_active IP Right Cessation
- 1992-01-27 DK DK92810056.9T patent/DK0502812T3/da active
- 1992-01-27 ES ES92810056T patent/ES2091438T3/es not_active Expired - Lifetime
- 1992-01-27 DE DE69212671T patent/DE69212671T2/de not_active Expired - Fee Related
- 1992-01-27 EP EP92810056A patent/EP0502812B1/fr not_active Expired - Lifetime
- 1992-02-03 CA CA002060544A patent/CA2060544C/fr not_active Expired - Fee Related
- 1992-02-04 IE IE920361A patent/IE72959B1/en not_active IP Right Cessation
- 1992-02-05 JP JP01990892A patent/JP3415171B2/ja not_active Expired - Fee Related
-
1996
- 1996-08-16 GR GR960401969T patent/GR3020809T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
IE72959B1 (en) | 1997-05-07 |
ATE141329T1 (de) | 1996-08-15 |
ES2091438T3 (es) | 1996-11-01 |
JPH05192183A (ja) | 1993-08-03 |
GR3020809T3 (en) | 1996-11-30 |
DE69212671T2 (de) | 1997-03-13 |
IE920361A1 (en) | 1992-08-12 |
DE69212671D1 (de) | 1996-09-19 |
CA2060544A1 (fr) | 1992-08-06 |
EP0502812A1 (fr) | 1992-09-09 |
EP0502812B1 (fr) | 1996-08-14 |
AU1042192A (en) | 1992-08-13 |
JP3415171B2 (ja) | 2003-06-09 |
AU662311B2 (en) | 1995-08-31 |
CA2060544C (fr) | 2002-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0502812T3 (da) | Rekombinante antistoffer, som er specifikke for en vækstfaktorreceptor | |
ATE366747T1 (de) | Menschliche monoklonale antikörper gegen den epidermalen wachstumsfaktorrezeptor | |
ATE241008T1 (de) | Monoklonale antikörper gegen den interferonrezeptor, mit neutralisierender aktivität gegen typ i-interferon | |
DE69638355D1 (de) | Anti-CD3-Antikörper zur Verwendung zur Induzierung von Immunsuppression | |
LU91116I2 (fr) | Cetuximab | |
IL93118A0 (en) | Expression vectors,cells transformed thereby and their use in the production of chimeric monoclonal antibodies | |
MX9201016A (es) | Anticuerpos monoclonales humanizados y quimericos | |
DK0712863T3 (da) | Humaniserede og kimæriske monoklonale antistoffer, som genkender epidermisvækstfaktor-receptor (EFG-R), diagnostiske og terapeutiske anvendelser | |
DE3687736D1 (de) | Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung. | |
ATE166882T1 (de) | Monoklonale antikörper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung | |
CA2126182A1 (fr) | Anticorps humanises reagissant avec le gpiib/iiia | |
DE3580524D1 (de) | Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen. | |
CY1107163T1 (el) | Συνδεδεμενα με γαγγλιοζιτη ανασυνδυασμενα αντισωματα και η χρησιμοποιηση αυτων στη διαγνωση και θεραπευτικη αγωγη ογκων |